Schizophrenia

AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia

Psychedelics And Schizophrenia: What's The Link?

Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia

Psychedelics And Schizophrenia: What's The Link?

Marketing & Marijuana: Why Responsibility Is So Important As Psychosis & Schizophrenia Among Youth Rise

Addex Expands Pipeline With Selective M4 PAM Program For Schizophrenia & Other Psychotic Disorders

Schizophrenia Recent News

Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial

Cannabis Increases Odds Of This Disorder In Teens Despite Infrequent Use

This article was originally published on The Fresh Toast and appears here with permission.

Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia

Alkermes plc's (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan)

FDA Gives Green Signal To Reviva Pharma's Late-Stage Schizophrenia Trial

The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it m

FDA Pushes Review Of BioXcel's Candidate For Agitation Associated With Neuropsychiatric Disorders

Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets

Neurocrine Biosciences Inc (NASDAQ: NBIX) has

ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study

Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

FDA Approves First And Only Twice-Yearly Schizophrenia Drug

Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review

Cerevel Therapeutics Stock Shoots Higher As Schizophrenia Treatment Tops Placebo On Antipsychotic Activity

Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med

BioXcel's Formulated Dexmedetomidine US Application For Agitation Under FDA Review

Minerva Shares Surge As Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning

Reviva Pharma Stock Trading Higher On Detailed Positive Schizophrenia Study Results

Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity

Neurocrine Biosciences Inc (NASDAQ: NBIX)

Psychedelics And Schizophrenia: What's The Link?

This article by Derek Beres was originally published on Psychedelic Spotlight, and appears here with permission. Psychedelics and schizophrenia share a history. Now, researchers are looking at how psychedelics may change the future. Can psychedelics help treat schizophrenia?

UPDATE: JMP Securities Initiates Coverage On Intra-Cellular Therapies